Pulmonary hemorrhage (or "pulmonary haemorrhage") is an acute bleeding from the lung, especially in the upper respiratory tract and the endotracheal tube. When evident clinically, the condition is usually massive, associated with bleeding in other sites as well as more than one third of the lungs. The onset of Pulmonary Hemorrhage is characterized by oozing of bloody fluid from the nose and endotracheal tube, as well as to a lesser extent in other places, accompanied by rapid worsening of patient respiration, cyanosis and, in severe cases, shock. Treatment should be immediate and should include tracheal suction, oxygen, positive pressure ventilation, and correction of underlying abnormalities (e.g. disorders of coagulation). A blood transfusion may be necessary.Read more on Wikipedia
* Warning: The facts and figures contained in these reports are accurate to the best of our capability; however, our metrics are only meant to augment your medical knowledge, and should never be used as the sole basis for selecting a new medication. As with any medical decision, be sure to work with your doctor to ensure the best choices are made for your condition.
* About FAERS: The FDA Adverse Event Reporting System (FAERS) is used by FDA for activities such as looking for new safety concerns that might be related to a marketed product, evaluating a manufacturer's compliance to reporting regulations and responding to outside requests for information. Reporting of adverse events is a voluntary process, and not every report is sent to FDA and entered into FAERS. The FAERS database may contain duplicate reports, the report quality is variable, and many factors may influence reporting (e.g., media attention, length of time a drug is marketed, market share). For these reasons, FAERS case reports cannot be used to calculate incidence or estimates of risk for a particular product or compare risks between products.